3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
60
Breast Neoplasms
54
Ovarian Neoplasms
35
Triple Negative Breast Neoplasms
28
Lung Neoplasms
25
Fallopian Tube Neoplasms
24
Endometrial Neoplasms
24
Neoplasm Metastasis
22
Squamous Cell Carcinoma of Head and Neck
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
19
Neoplasms
15
Esophageal Neoplasms
13
Esophageal Squamous Cell Carcinoma
12
Carcinoma, Ovarian Epithelial
10
Stomach Neoplasms
9
Head and Neck Neoplasms
9
Carcinoma
9
Colorectal Neoplasms
8
Adenocarcinoma Of Esophagus
7
Adenocarcinoma
7
Peritoneal Neoplasms
6
Uterine Cervical Neoplasms
5
Melanoma
5
Small Cell Lung Carcinoma
4
Oropharyngeal Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Respiratory Tract Neoplasms
3
Recurrence
3
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Paclitaxel
×
90 days
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled